Drug Profile


Alternative Names: Flisint; Fumagiline; SR 90144

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antifungals; Antineoplastics; Cyclohexanes; Sesquiterpenes; Unsaturated fatty acids
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Microsporidiosis

Highest Development Phases

  • Marketed Microsporidiosis

Most Recent Events

  • 17 Mar 2009 Launched for Microsporidiosis in France (PO)
  • 20 Oct 2005 A study has been added to the Parasitic Infections therapeutic trials section
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top